T2N0M0 esophageal cancer.

Area of Science:

• Oncology
• Surgical Oncology
• Clinical Research

Background:

• Accurate clinical staging of esophageal cancer is essential for effective treatment planning.
• Esophageal cancer staging errors can lead to overtreatment or undertreatment, impacting patient outcomes.

Purpose of the Study:

• To develop a treatment algorithm for clinical T2N0M0 (cT2N0M0) esophageal cancer.
• To identify errors in clinical staging and the consequences of misstaging.

Main Methods:

• Retrospective analysis of 742 clinically staged esophageal cancer patients.
• Comparison of survival rates between different treatment strategies (surgery alone, surgery with adjuvant therapy, induction therapy followed by surgery).
• Statistical analysis using log-rank test for survival comparisons.

Main Results:

• The positive predictive value of cT2N0M0 for pathological T2N0M0 (pT2N0M0) was only 13%.
• Of incorrectly staged cT2N0M0 cancers, 63% were overstaged (mostly pT1) and 37% were understaged (mostly pN1).
• Understaged patients receiving postoperative adjuvant therapy showed improved survival compared to surgery alone.

Conclusions:

• Surgery with lymphadenectomy is recommended as the initial treatment for cT2N0M0 esophageal cancer.
• Postoperative adjuvant therapy should be administered to clinically understaged patients.
• Patients with true pT2N0M0 esophageal cancer achieve acceptable survival with surgery alone.